• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epidemiol Health . Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the

tetano

Editor, Senior Moderator
Epidemiol Health


. 2022 Sep 30;e2022085.
doi: 10.4178/epih.e2022085. Online ahead of print.
Seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies during the third wave of coronavirus disease in the Seoul metropolitan area of Korea


Kyuhyun Yoon[SUP] 1 [/SUP], Jayeun Kim[SUP] 2 [/SUP], Kyong Ran Peck[SUP] 3 [/SUP], Hyun Soo Kim[SUP] 4 [/SUP], Hyukmin Lee[SUP] 5 [/SUP], Yoo-Sung Hwang[SUP] 6 [/SUP], Soon Young Lee[SUP] 7 [/SUP], Sung-Il Cho[SUP] 8 [/SUP], Hun Jae Lee[SUP] 9 [/SUP], Yeongyeong Kim[SUP] 10 [/SUP], Brian Byoungguk Kim[SUP] 11 [/SUP], June-Woo Lee[SUP] 11 [/SUP], Ah-Ra Kim[SUP] 11 [/SUP], HyeonNam Do[SUP] 11 [/SUP], Dong-Hyun Kim[SUP] 12 [/SUP]



Affiliations

Abstract

Objectives: After the third wave of coronavirus disease (COVID-19), by mid-February 2021, approximately 0.16% of the population was confirmed positive, which appeared to be one of the lowest rates worldwide at that time. However, asymptomatic transmission poses a challenge for COVID-19 surveillance. Therefore, a community-based serosurvey of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted to understand the effectiveness of Korea's strong containment strategy.
Methods: We collected 5,002 residual sera samples from January 30 to March 3, 2021 from 265 medical facilities in Seoul, 346 in Kyunggi-do' and 57 in Incheon. Among them, 60 samples from tertiary institutions were excluded. We defined the sub-regions according to the addresses of the medical facilities where the specimens were collected. Elecsys Anti-SARS-CoV-2 was used for the screening test, and positivity was confirmed using the SARS-CoV-2 sVNT Kit. Prevalence was estimated using sampling weight and the Wilson score interval for a binomial proportion with a 95% confidence interval.
Results: Among the 4,942 specimens, 32 and 25 tested positive for COVID-19 in the screening and confirmatory tests, respectively. The overall crude prevalence of SARS-CoV-2 antibody was 0.51%. The population-adjusted overall prevalence was 0.55% in women and 0.38% in men. The region-specific estimation was 0.67% and 0.30% in Gyeonggi-do and Seoul, respectively. No positive cases were detected in Incheon.
Conclusion: The proportion of undetected cases in South Korea remains low. Therefore, an infection control strategy with exhaustive tracing and widespread pre-emptive testing appears to be effective in containing the spread of the virus in the community.

Keywords: Asymptomatic; Coronavirus disease; Cumulative incidence; Seroprevalence; Severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom